Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
about
sameAs
Structural basis of HIV-1 resistance to AZT by excisionImpact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateNovel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineK65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenineHigh-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseNevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyMutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistanceResistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptaseSusceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsNovel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell cultureA mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitorsRapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptaseMechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosinepol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cellsCharacterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitorHuman immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugsResistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsThe same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineStandardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance WorSelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anPreclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replicationSignificance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityNovel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitroAn in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineAntiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionZidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseMutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme.Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Clinically relevant genotype interpretation of resistance to didanosineSwitch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.
P2860
Q24596976-729EFA09-62B6-4F00-9303-65AB1736DDADQ26851997-AC7032A1-A861-4B8F-8601-3B673EF67B71Q28250395-57D0A426-9391-45E8-A696-14143F9CDA35Q28342653-64ACF874-7B91-4B2A-91C4-5DF7B44BC1FCQ28342745-B7BEB18D-94FB-4C03-A86D-55C84A204133Q28344137-A28DB4AC-15B6-41AF-849B-F0AC4BFDB745Q28367386-4844CDA8-AB59-4526-AE75-7151F89DC96EQ28367493-0A5E0D23-F4C5-4284-A78B-4EFE928B1944Q28367526-A32151DC-F0A6-4D5A-8C79-DABAA1EEDD34Q28367539-44F6547B-CC89-4079-A45D-61C31332DA9FQ28367547-C1BBF6B3-182A-457D-8902-B18EBA15607EQ28367590-877CA407-230B-4B94-B1D1-92DC8CD4E7EFQ28367594-85C79F08-390B-456B-A091-1FE2789EED2EQ28368028-B960AE4A-63ED-4924-A5B6-3707851DB027Q28368030-5CC5C577-5CA5-427E-866D-33BD3AC13B16Q28368041-6A871ADD-A5CF-48C3-AC99-A6D666DAD5CEQ28368048-70D401B2-30AE-40CF-8F84-028ABC620537Q28369167-3E455E54-F8E4-42D6-A9A4-171018067FEDQ28369354-F3413407-79E2-4C09-BE0E-966BCD5EED17Q28369516-0834FD35-51C1-474A-808A-BA26A4D92B08Q28378322-E6E930AE-0459-4D6C-B8C1-DDDC1BAF2935Q28378547-58E956AA-62CB-4879-A557-C7DFE187A16DQ28378626-784B02C3-2AA3-404C-9EA6-6478A3EF93B1Q28378727-41700229-855B-4E3F-8FFA-38A6894F2A65Q28378760-E0F09F91-25A1-4972-8F3D-1F112781ED6EQ28378825-3C048A28-A095-4F5F-B459-AB671B313A11Q28378951-C4A53BA5-00F1-4766-99F1-AD3435166FB7Q28379249-224CA949-3288-47C4-AFC5-9E55666D1BB8Q28379270-A063D3D0-60CE-4262-8716-99FC5F16D961Q28379497-2FF39D39-B8CA-4149-B949-7B7597D65A29Q28379499-345E4873-4F00-4BF1-B811-FFC896F0A972Q28379552-7786392B-F934-439D-83B8-B3F83616AF94Q28471689-9EAB0E2F-2CE9-46AB-95B1-0EA5842EB5A2Q28478993-B8A3EA9B-7AB3-4975-988A-694841B516B6Q28481004-F0BD7081-E09B-4FD1-BCAB-A6A471331E4BQ30658869-9A874F23-B063-4398-9134-73A0EE1C61D2Q33749177-200724D8-B9C1-4AE5-BF6D-01F6CC09AD5EQ33770146-31D7E899-7704-4F08-B975-136B412498FFQ33782562-FF82D2BE-581A-4AA4-A8B3-3A6C1AB80325Q33787173-D010090D-B39E-4780-9796-F985C394948A
P2860
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Fifth mutation in human immuno ...... level resistance to zidovudine
@ast
Fifth mutation in human immuno ...... level resistance to zidovudine
@en
Fifth mutation in human immuno ...... level resistance to zidovudine
@nl
type
label
Fifth mutation in human immuno ...... level resistance to zidovudine
@ast
Fifth mutation in human immuno ...... level resistance to zidovudine
@en
Fifth mutation in human immuno ...... level resistance to zidovudine
@nl
prefLabel
Fifth mutation in human immuno ...... level resistance to zidovudine
@ast
Fifth mutation in human immuno ...... level resistance to zidovudine
@en
Fifth mutation in human immuno ...... level resistance to zidovudine
@nl
P2860
P356
P1476
Fifth mutation in human immuno ...... level resistance to zidovudine
@en
P2093
B A Larder
C A Boucher
P2860
P304
P356
10.1073/PNAS.89.5.1934
P407
P50
P577
1992-03-01T00:00:00Z